Your browser doesn't support javascript.
loading
Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients.
Wu, Tzong-Yow; Chen, Pao-Yu; Wang, Jann-Tay; Liu, Wang-Da; Chen, Yee-Chun; Chang, Shan-Chwen.
Afiliação
  • Wu TY; Department of Internal Medicine, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei 100, Taiwan.
  • Chen PY; Department of Internal Medicine, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei 100, Taiwan.
  • Wang JT; Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.
  • Liu WD; Department of Internal Medicine, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei 100, Taiwan.
  • Chen YC; National Institutes of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan, Taiwan.
  • Chang SC; Department of Internal Medicine, National Taiwan University Cancer Center, Taipei, Taiwan.
J Antimicrob Chemother ; 79(5): 1196-1200, 2024 05 02.
Article em En | MEDLINE | ID: mdl-38538154
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antivirais / Adenosina / Monofosfato de Adenosina / Hospedeiro Imunocomprometido / Alanina / Quimioterapia Combinada / SARS-CoV-2 / Tratamento Farmacológico da COVID-19 Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antivirais / Adenosina / Monofosfato de Adenosina / Hospedeiro Imunocomprometido / Alanina / Quimioterapia Combinada / SARS-CoV-2 / Tratamento Farmacológico da COVID-19 Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article